日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

尼洛替尼联合紫杉醇治疗晚期实体瘤患者的I期研究

Shin, Sarah J; O'Sullivan Coyne, Geraldine; Kummar, Shivaani; Miller, Sarah B; Johnson, Barry C; Anderson, Larry; Rubinstein, Larry; Miller, Brandon; Wilsker, Deborah F; Ferry-Galow, Katherine V; Piekarz, Richard; Zlott, Jennifer; Hogu, Murielle; Juwara, Lamin; Krushkal, Julia; Konaté, Mariam; Palmisano, Alida; Zhao, Yingdong; Collins, Jerry; Parchment, Ralph E; Doroshow, James H; Chen, Alice P

TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models

TET2 和 DNMT3A 突变以及人类实体瘤模型中对 4'-硫代-2'-脱氧胞苷的特殊反应

Sherry X Yang, Melinda Hollingshead, Larry Rubinstein, Dat Nguyen, Angelo B A Larenjeira, Robert J Kinders, Michael Difilippantonio, James H Doroshow

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

帕唑帕尼与替凡替尼联合治疗可调节难治性晚期实体肿瘤中的 VEGF 和 c-MET 水平

Shivaani Kummar, Apurva K Srivastava, Tony Navas, Fabiola Cecchi, Young H Lee, Donald P Bottaro, Sook Ryun Park, Khanh T Do, Woondong Jeong, Barry C Johnson, Andrea R Voth, Larry Rubinstein, John J Wright, Ralph E Parchment, James H Doroshow, Alice P Chen

Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

静脉注射 5-氟-2'-脱氧胞苷与四氢尿苷联合使用可增加晚期实体瘤患者中表达 p16 的循环肿瘤细胞的比例

Geraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M Covey, Jan H Beumer, Mihaela C Cristea, Edward M Newman, Stephen Koehler, Jorge J Nieva, Agustin A Garcia, David R Gandara, Brandon Miller, Sonny Khin, Sarah B Miller, Seth M Steinberg, Larry Rubinstein, Ralph E Parchmen

Notch1 phenotype and clinical stage progression in non-small cell lung cancer

非小细胞肺癌中的 Notch1 表型和临床分期进展

Dat Nguyen, Larry Rubinstein, Naoko Takebe, Lucio Miele, Joseph E Tomaszewski, Percy Ivy, James H Doroshow, Sherry X Yang

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

模拟人类外周血单核细胞对聚(ADP-核糖)聚合酶抑制剂 ABT-888 的药效学反应

Jiuping Ji, Robert J Kinders, Yiping Zhang, Larry Rubinstein, Shivaani Kummar, Ralph E Parchment, Joseph E Tomaszewski, James H Doroshow

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

聚(ADP-核糖)聚合酶抑制剂 ABT-888 治疗晚期恶性肿瘤患者的 0 期临床试验

Shivaani Kummar, Robert Kinders, Martin E Gutierrez, Larry Rubinstein, Ralph E Parchment, Lawrence R Phillips, Jiuping Ji, Anne Monks, Jennifer A Low, Alice Chen, Anthony J Murgo, Jerry Collins, Seth M Steinberg, Helen Eliopoulos, Vincent L Giranda, Gary Gordon, Lee Helman, Robert Wiltrout, Joseph E

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts

期临床试验的临床前建模:小鼠异种移植肿瘤活检中聚(ADP-核糖)聚合酶的药效学测定鉴定

Robert J Kinders, Melinda Hollingshead, Sonny Khin, Larry Rubinstein, Joseph E Tomaszewski, James H Doroshow, Ralph E Parchment; National Cancer Institute Phase 0 Clinical Trials Team